NYSE$EBS
Emergent BioSolutions Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Emergent BioSolutions reported Q4 2024 revenue of $194.7M, a net loss of $31.3M.
For Q4 2024, Emergent BioSolutions reported Revenue was $194.7M, net loss was $31.3M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $194.7M for Q4 2024.
- Net loss $31.3M.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Emergent BioSolutions · Revenue · Quarterly
$195M
Revenue by segment
Emergent BioSolutions · $108M total across 3 segments · Q3 2023
- Other Products$50.1M+99.6%46.5%
- Anthrax MCM$32.9M—30.5%
- Smallpox MCM$24.7M—22.9%
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and trial outcomes affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.5%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-1.0%
Avg return
30 days after
47%
30 / 64 earnings
Positive
+75.5%
Q1 2024
Best reaction
-41.2%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | +13.3% | +13.5% | |
| Q4 2025 | -27.1% | -21.0% | -28.6% | |
| Q3 2025 | +36.9% | +7.3% | +18.8% | |
| Q1 2025 | +35.0% | +24.1% | +39.9% | |
| Q4 2024 | -6.4% | -15.5% | -29.3% | |
| Q3 2024 | +22.8% | +33.6% | +0.6% | |
| Q2 2024 | -41.2% | -27.1% | -21.5% | |
| Q1 2024 | +75.5% | +111.7% | +203.2% | |
| Q4 2023 | -18.8% | -17.9% | -32.8% | |
| Q3 2023 | -8.9% | -22.9% | +5.5% | |
| Q2 2023 | -20.0% | -25.9% | -40.9% | |
| Q1 2023 | +18.5% | +0.7% | -8.0% | |
| Q4 2022 | -9.7% | -15.0% | -31.8% | |
| Q3 2022 | -36.7% | -22.5% | -38.6% | |
| Q2 2022 | -12.6% | -8.6% | -30.7% | |
| Q1 2022 | -11.2% | -8.5% | -3.4% | |
| Q4 2021 | -6.7% | -2.2% | +4.1% | |
| Q3 2021 | -37.0% | -33.3% | -20.3% | |
| Q2 2021 | +1.1% | -2.7% | -1.5% | |
| Q1 2021 | -1.7% | -4.8% | -2.3% | |
| Q4 2020 | -15.9% | -23.7% | -25.7% | |
| Q3 2020 | -6.1% | -10.9% | -15.8% | |
| Q2 2020 | +18.1% | +30.1% | +24.8% | |
| Q1 2020 | +6.4% | +7.5% | +12.9% | |
| Q4 2019 | +2.1% | -7.2% | -23.6% | |
| Q3 2019 | -5.4% | -7.6% | -5.4% | |
| Q2 2019 | +1.5% | +0.7% | -0.8% | |
| Q1 2019 | -8.0% | -9.2% | -23.7% | |
| Q4 2018 | -2.8% | -11.0% | -25.8% | |
| Q3 2018 | +6.0% | +12.6% | +19.0% | |
| Q2 2018 | +3.9% | +0.2% | +13.8% | |
| Q1 2018 | -4.0% | -4.9% | +1.4% | |
| Q4 2017 | -3.0% | +0.6% | +6.6% | |
| Q3 2017 | +7.0% | -3.6% | +9.1% | |
| Q2 2017 | -1.1% | -1.2% | +4.2% | |
| Q1 2017 | -3.5% | +3.2% | +5.6% | |
| Q4 2016 | +0.1% | +4.9% | -3.7% | |
| Q3 2016 | +9.8% | +22.0% | +4.7% | |
| Q2 2016 | -2.1% | -2.6% | -11.6% | |
| Q1 2016 | +0.9% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +2.5% | — | — | |
| Q2 2015 | +5.2% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +7.6% | — | — | |
| Q2 2014 | -2.6% | — | — | |
| Q1 2014 | -10.5% | — | — | |
| Q4 2013 | +9.1% | — | — | |
| Q3 2013 | +9.1% | — | — | |
| Q2 2013 | +1.6% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q3 2012 | +8.4% | — | — | |
| Q2 2012 | +1.1% | — | — | |
| Q1 2012 | +4.9% | — | — | |
| Q4 2011 | +4.6% | — | — | |
| Q1 2011 | +4.6% | — | — | |
| Q4 2009 | +8.1% | — | — | |
| Q3 2011 | -5.3% | — | — | |
| Q3 2010 | -5.3% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -1.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro